In Oncology, Antibody-Drug Conjugates Are a Hot Ticket
The antibody-drug conjugate (ADC) class has seen substantial growth since the first FDA approval of an ADC, Pfizer’s Mylotarg (gemtuzumab ozogamicin), in 2000. Mylotarg, which was used to treat patients with acute myeloid leukemia, wound up dampening some …